WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > BioPlus Specialty Pharmacy
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Pharmacy Market
Rx Linc | October 08, 2021
Rx Linc, an emerging Business Intelligence pharmacy Switch network, and Scriptera, an organization whose mission is to create data opportunities for their health care partners, announced a strategic partnership that enables pharmacies to monetize their market-level data through a unique revenue sharing program. We are very excited and pleased to bring Scriptera's data platform and industry opportunities to Rx Linc's Switch Network. Rx Linc is focused on deliv...
WBRZ- | March 30, 2020
Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pandemic. "On behalf of Louisiana, I want to thank Amneal for this generous donation," said General Landry. "Amneal's donation is one step toward trying to find treatments and cures f...
PharmaTimes | March 30, 2020
AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET ...
Prnewswire | August 28, 2020
Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. "We are looking to commercialize a product as soon as possible," says Jesse John Francis Clark, founder of Fixx. "We are going to develop ...
Whitepaper
Article
PHARMACY MARKET
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE